ClinicalTrials.gg

Program

Lutetium Lu 177 NYM032

Its studies are mostly in Prostatic Neoplasms, led by Norroy Bioscience.

Furthest: phase 3, since Aug 26, 20262 company-led studies, 2 open or runningNext primary completion: Nov 30, 2028 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Norroy Bioscience22 open or runningphase 3since Aug 26, 2026Apr 17, 2024Nov 30, 2028phase 3 · NCT07795268

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 17, 2024First study: phase 2 study in Metastatic Castration-resistant Prostate CancerFirst studyNCT06383052 · 30 enrolled · China
  2. Aug 26, 2026Phase 3 study in Prostatic NeoplasmsPhase 3 reachedNCT07795268 · 600 planned

Ahead

  1. Nov 30, 2028Primary completion: phase 3 study in Prostatic NeoplasmsNCT07795268

TargetBeta

FOLH1 →read by rule
“A radioconjugate composed of NYM032, a human prostate-specific membrane antigen (PSMA)-targeting ligand, ”NCIt, by rule

Other programs on FOLH1

ProgramCompanyFurthest phaseStudies
flotufolastat F 18ruleBraccophase 47
piflufolastatruleLantheusphase 45
abefolastat tesaroxetan CU-64ruleclarity-pharmaceuticals-ltdphase 35
gallium 68 PSMA-11ruleNovartisphase 34
Lutetium Lu 177 Ludotadipeprulefuturechemphase 33
Anti-PSMA/Anti-CD28 Bispecific Antibody JNJ-87189401Johnson & Johnsonphase 32
actinium AC-225 vipivotide tetraxetanNovartisphase 32
HRS-4357Jiangsu HengRui Medicinephase 32
zadavotide guraxetanAstraZenecaphase 24
AB-001rulefrontier-biotechnologies-incphase 23
olsutamigruleRegeneron Pharmaceuticalsphase 22
SHR-4394Jiangsu HengRui Medicinephase 22

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07795268Prostatic Neoplasms3Not yet recruitingNov 30, 2028600
NCT06383052Metastatic Castration-resistant Prostate Cancer · China2Active, not recruitingJun 30, 202530

How it is read

Names in the registry

  • “177Lu-NYM032 injection”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.